In an interview with Venture Capital Journal, Dr. Razmi discussed the state of venture industry, investments in health AI to date, and what it will take for investors and entrepreneurs to accelerate the diffusion of AI into healthcare and life sciences.
From the article:
“A lot of investment has gone into use cases that so far haven’t really shown any benefit,” Razmi told Venture Capital Journal. “Because of the risk to the patients, because of the convoluted nature of the industry where the buyer is not the user… you have to navigate a bigger maze in order to bring innovations into healthcare.”
Razmi’s co-founder, Brian Beeler, was previously a corporate officer at several healthcare companies, most recently at Horizon Therapeutics, the Ireland-based biotech company that Amgen acquired last year for $27.8 billion. Beeler was also on the management team of other companies that have had successful exits, such as Schwarz Pharma, which was acquired by UCB for $5.6 billion in 2006, and medical device company Fenwal Holdings, which Fresenius Kabi acquired for $1.1 billion in 2012.
